Last reviewed · How we verify

Radiesse, Xeomin, Belotero — Competitive Intelligence Brief

Radiesse, Xeomin, Belotero (Radiesse, Xeomin, Belotero) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dermal fillers and neurotoxin. Area: Dermatology/Aesthetics.

marketed Dermal fillers and neurotoxin Dermatology/Aesthetics Small molecule Live · refreshed every 30 min

Target snapshot

Radiesse, Xeomin, Belotero (Radiesse, Xeomin, Belotero) — Main Line Center for Laser Surgery. These are injectable dermal fillers and botulinum toxin products that restore facial volume, smooth wrinkles, and enhance facial contours through different mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Radiesse, Xeomin, Belotero TARGET Radiesse, Xeomin, Belotero Main Line Center for Laser Surgery marketed Dermal fillers and neurotoxin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dermal fillers and neurotoxin class)

  1. Main Line Center for Laser Surgery · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Radiesse, Xeomin, Belotero — Competitive Intelligence Brief. https://druglandscape.com/ci/radiesse-xeomin-belotero. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: